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Rubella virus (RUBV) replicons expressing a drug resistance gene and a gene of interest were used to
select cell lines uniformly harboring the replicon. Replicons expressing GFP and a virus capsid protein
GFP fusion (C-GFP) were compared. Vero or BHK cells transfected with either replicon survived drug
selection and grew into a monolayer. However, survival was 9-fold greater following transfection
with the C-GFP-replicon than with the GFP-expressing replicon and while the C-GFP-replicon cells grew
similarly to non-transfected cells, the GFP-replicon cells grew slower. Neither was due to the ability of
the CP to enhance RNA synthesis but survival during drug selection was correlated with the ability of CP
to inhibit apoptosis. Additionally, C-GFP-replicon cells were not cured of the replicon in the absence of
drug selection. Interferon-alpha suppressed replicon RNA and protein synthesis, but did not cure the
cells, explaining in part the ability of RUBV to establish persistent infections.
& 2012 Elsevier Inc. All rights reserved.Introduction
Rubella virus (RUBV), the sole member of the Rubivirus genus in
the family Togaviridae, is a plus strand RNA virus with a genome of
10 kb that contains two open reading frames (ORF’s): the 50
proximal ORF or NS-ORF encodes a precursor which is cleaved to
produce the two replicase proteins P150 and P90 while the 30
proximal ORF or SP-ORF encodes the virion proteins CP (capsid
protein), E1 and E2 (envelope glycoproteins) (Frey, 1994). The
NS-ORF is translated from the genome RNA while the SP-ORF is
translated from a subgenomic (SG) RNA synthesized in infected cells.
By manipulation of a RUBV infectious cDNA clone, monocistronic
replicons have been developed in which the SP-ORF is replaced with a
foreign gene (Tzeng et al., 2001). Using an internal ribosome entry site
or IRES, bicistronic replicons expressing two foreign genes have also
been generated (Fontana et al., 2007; Pugachev et al., 2000).
In addition to replicons that express a foreign gene in the initially
transfected cell (replicons cannot spread from cell to cell without an
independent source of virion proteins), replicons expressing a drug
resistance gene have been used to select cell cultures that uniformly
harbor the replicon (Blight et al., 2000; Frolov et al., 1999; Graff et al.,
2006; Liu et al., 2004; Lohmann et al., 2003; Mackenzie et al., 2001;
Perri et al., 2000; Pﬂugheber et al., 2002; Zhu et al., 2003). Such cell
cultures are useful in characterizing the intracellular replication of
viruses that multiply poorly in cell culture. RUBV multiplies in a
number of standard cell culture lines, but in all cell culture linesll rights reserved.
rs for Disease Control andtested, RUBV replication is slow and asynchronous and often com-
plete infection of cells in the culture is not achieved, making the virus
replication cycle difﬁcult to study (Frey, 1994). We therefore intro-
duced a drug resistance gene into the RUBV bicistronic replicon for
the purpose of selecting uniformly transfected cultures. By using the
bicistronic replicon, we were also able to characterize the effect of an
independent protein on replicon replication and the phenotype of the
transfected cell. For this initial study, we chose the virus CP, a
multifunctional protein which in addition to forming the core or
nucleocapsid within the virus particle has also been shown to:
enhance replicon RNA synthesis (Tzeng et al., 2006); modulate
genomic and SG RNA synthesis (Tzeng and Frey, 2005); rescue a
lethal mutation in the replicase gene (Tzeng and Frey, 2003); bind to
poly A-binding protein blocking translation (Ilkow et al., 2008), inhibit
mitochondrial transport (Ilkow et al., 2010a), and suppress apoptosis
(Ilkow et al., 2011) (for review: see (Ilkow et al., 2010c). Intriguingly,
we found that CP enhanced survival of the transfected cells during
drug selection and was necessary for the replicon-containing cells to
maintain a normal growth rate. In addition, RUBV readily establishes
a persistent infection in cell culture (Mifune et al., 1970; Stanwick and
Hallum, 1974) and we thus also used the replicon-containing cultures
to determine the stability of the replicons and the ability of Type I
interferon (IFN) to cure the cells of the replicon, with the intriguing
ﬁnding that it was unable to do so.Results
Transfection, drug selection, and properties of drug-selected cell lines
Genomic diagrams of the replicons used in this study are shown in
Fig. 1A. In RUBrep/GFP/neo, the SG promoter is followed by the GFP
Fig. 1. Replicon-transfected cell survival and growth following drug selection. (A). Genomic diagrams of RUBV and the replicons used in this study. (B). Reverse plaque
assay of Vero cells transfected with RUBrep/GFP/neo or RUBrep/C-GFP/neo. Four days post-transfection, cells were subcultured at the indicated dilution in medium
containing G418. The cultures were stained with crystal violet to visualize the density of viable cells two weeks later. (C) GFP expression in drug selected RUBrep/GFP/neo-,
RUBrep/C-GFP/neo-, and RUBrep/CR5A-GFP/neo-transfected cells. Nuclei were stained with Hoechst 33342. (D) Growth rate of Vero in comparison with drug-selected
RUBrep/GFP/neo-, RUBrep/C-GFP/neo-, and RUBrep/CR5A-GFP/neo-transfected cells. Approximately 5105 cells were plated in replicate culture dishes and the total
number of cells was determined on the days indicated. Replicon-transfected cells were grown in the presence of G418 while Vero cells were grown in medium without
antibiotic. The results are the means of three independent experiments, the error bars represent the standard deviation from the mean.
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GFP/neo contains a C-GFP fusion. The C-GFP fusion in this construct
contains all 300 aa of CP. It is to be noted that in our previous studies,
only the N-terminal 88 aa of CP were required in the fusion protein to
modulate genome and SG RNA synthesis (Tzeng and Frey, 2005) and
rescue the P150 NotI deletion mutant (Tzeng and Frey, 2003).
Vero cells transfected with both replicons were treated with
antibiotic G418 four days post-transfection. As shown in Fig. 1B, cells
surviving the drug treatment were readily selected, however cell
survival was roughly nine times greater in the culture transfected
with RUBrep/C-GFP/neo than the culture transfected with RUBrep/
GFP/neo. When both replicons were tested in BHK cells, similar
results were obtained as in Vero cells (data not shown), indicating
that this cell survival phenomenon was not cell-type speciﬁc. In
addition, cell survival was also approximately nine times greater in
the cultures transfected with the corresponding replicons expressing
the puromycin acetylase gene, PAC [RUBrep/C-GFP/PAC and RUBrep/GFP/PAC, respectively (data not shown)], demonstrating that this cell
survival phenomenon was not drug speciﬁc as well.
After drug selection and generation of conﬂuent monolayers,
cultures transfected with both replicons were subcultured and passed
in the presence of antibiotic. As shown in Fig. 1C, the GFP expressed in
the RUBrep/GFP/neo-transfected cultures was distributed nonspeciﬁ-
cally throughout the cell, including the nucleus, while the C-GFP
fusion expressed in the RUBrep/C-GFP cultures had a cytoplasmic
distribution with a concentration around the nuclear membrane in
the cells with the strongest signal, typical of the distribution of CP in
RUBV-infected cells (Frey, 1994). Interestingly, a higher percentage of
the cells in the RUBrep/GFP/neo-transfected cultures (88%) exhib-
ited detectable GFP expression than in the RUBrep/C-GFP/neo-trans-
fected cultures (23%). In addition, to maintain the cultures the
RUBrep/GFP/neo cells had to be subcultured at a dilution of ¼ while
the RUBrep/C-GFP/neo cells could be subcultured at a dilution of 1/10,
similar to routine subculturing of Vero cells. As shown in Fig. 1C,
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ing a conﬂuent culture of Vero cells at a dilution of 1/10), the growth
rate of the RUBrep/C-GFP/neo cells was similar to that of Vero cells,
while the growth rate of the RUBrep/GFP/neo cells was much slower
and the cells never reached conﬂuency. When examined by ﬂuores-
cence activated cell sorting following propidium iodide staining, no
differences in the cell cycle distribution were observed between
RUBrep/GFP/neo- and RUBrep/C-GFP/neo-transfected cells (analyses
were done on days 1 through 4 post-plating, data not shown).Mechanism behind the difference in cell survival and cell growth
Our initial hypothesis on the mechanism behind the profound
effect that CP exerted on survival and growth of the replicon-Fig. 2. Analyses of mechanism of C-mediated cell survival (A) and (B). Replicon-speciﬁ
electrophoresis, transferred to nitrocellulose, and probed with 32P-labeled, nick-transla
are indicated (it is to be noted that these vary in size between different replicons). Show
neo or RUBrep/C-GFP/neo. Shown in (B) is RNA isolated from cells transfected with the
26 weeks maintenance in the presence of G418 (RNA from both a population and a cl
lysates were resolved by SDS-PAGE, transferred to nitrocellulose and probed with antib
mock-transfected Vero cells, RUBrep/GFP/neo and RUBrep/C-GFP/neo-transfected Vero
presence of G418 for 26 weeks. (D) Reverse plaque assay of Vero cells transfected with
C(-S)GFP construct (see Fig. 1) contains aa 1–277 of C, ie lacking the C-terminal 23 aatransfected cultures following selection was that CP mediated more
efﬁcient replicon replication and therefore a higher level of neoR gene
product given the involvement of CP in virus RNA replication (Tzeng
and Frey, 2003, 2005). We therefore analyzed replicon RNA accumu-
lation following transfection up to and at the time of drug selection
(days 1 through 4 following transfection) and in transfected cultures
after drug selection. As shown in Fig. 2A, replicon RNA accumulation
was more rapid in RUBrep/C-GFP/neo-transfected cells than in
RUBrep/GFP/neo-transfected cells. However by day 4 post-transfec-
tion, the day antibiotic treatment was initiated, the amount of SG
RNA was equivalent. As we reported previously (Tzeng and Frey,
2005), CP modulates an increase in genome RNA production relative
to SG RNA production and this effect was evident in that RUBrep/C-
GFP/neo produced more genomic RNA than did RUBrep/GFP/neo. As
shown in Fig. 2B, in selected cultures the amount of SG RNA inc RNAs assayed by northern blotting. Total cell RNA was resolved by agarose gel
ted pGEM/GFP (a plasmid containing the GFP gene). The genomic (G) and SG RNAs
n in (A). is RNA isolated from cells on days 1–4 post-transfection with RUBrep/GFP/
same replicons on day 4 post-transfection, after 2 weeks of drug-selection, or after
onally derived line are shown). (C) NeoR factor assayed by Western blotting. Cell
odies against the neoR factor or calnexin (as a loading control). Lysates were from
cells at 2 and 4 days post-transfection or after selection and maintenance in the
RUBrep/C(-S)GFP/neo or RUBrep/C-GFP/neo followed by selection with G418. The
which serve as the signal sequence for E2.
Fig. 3. Replicon stability following drug release. RUBrep/GFP/neo and RUB/C-GFP/
neo-transfected Vero cells that had been selected and maintained in the presence
of G418 for 12 weeks were transferred to medium without G418 and subcultured
on a weekly basis. P0 refers to the last passage in the presence of drug while P1,
P2, etc. refer to weekly passages 1, 2, etc. in absence of drug. A northern blot was
performed to detect the presence of replicon-speciﬁc RNAs after the indicated
passages.
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even in cultures maintained for 26 weeks after selection. The
characteristic phenotypic ratios of genomic/SG RNA characteristic
for each replicon were maintained in selected cultures over this time
period and alterations in the replicon RNAs, such as deletions or
generation of DI RNAs, were not apparent. We also measured the
amount of neoR gene product in transfected cells. As shown in Fig. 2C,
at day 2 transfection more neoR gene product was present in RUBrep/
C-GFP/neo-transfected cells than in RUBrep/GFP/neo-transfected
cells, consistent with the greater abundance of replicon RNA in the
former cells. But by day 4 post-transfection, the day of antibiotic
treatment, the amount of neoR gene product was equivalent in the
two cultures. Similarly, the amount of neoR gene product was
equivalent in cultures following selection. Therefore, our hypothesis
that the effect of CP on cell survival and growth under drug selection
was mediated at the level of efﬁciency of replicon replication did not
appear to be correct.
We next took a genetic approach to conﬁrm that replicon RNA
synthesis was unrelated to cell survival after drug selection by
additionally constructing replicons expressing progressive C-term-
inal deletions of CP fused with GFP. We published previously (Tzeng
and Frey, 2003, 2005) that a fusion consisting of the N-terminal 88
residues of CP fused with GFP is sufﬁcient to rescue P150 mutants
with the NotI deletion and modulate the ratio of genomic/SG RNA
synthesis. As shown in Fig. 2D, survival of cells transfected with the
ﬁrst replicon in this series, one expressing a fusion protein consist-
ing of the residue 1–277 of CP (lacking the E2 signal sequence) fused
with GFP (Fig. 1A), was 9 fold lower than cells transfected with the
RUBrep/C-GFP/neo replicon. This result was also obtained with
replicons expressing fusion proteins with progressively larger
C-terminal deletions of CP (data not shown). Thus, the participation
of CP in replicon RNA synthesis was unrelated to survival of
transfected cells following drug selection. This result also indicated
that membrane association of CP was necessary for enhanced cell
survival during drug selection.
Ilkow et al. (2011) recently showed that RUBV CP inhibited Bax-
mediated apoptosis in a number of cell lines, including Vero, and that
the presence of the E2 signal sequence as well as ﬁve R residues
immediately upstream from the E2 signal sequence were necessary
for this inhibition. Reasoning that at least the greater survival during
drug selection exhibited by RUBrep/C-GFP/neo-transfected cells in
comparison to RUBrep/GFP/neo-transfected cells could be due to the
antiapoptotic activity of CP, we constructed a C-GFP replicon contain-
ing substitutions of the ﬁve R residues with A (CR5A), a mutation that
Ilkow et al. (2011) showed to eliminate the ability of CP to inhibit
apoptosis (Fig. 1A). Consistent with our hypothesis, survival following
drug selection of the cells transfected with the CR5A replicon was 9
fold lower than with the C-GFP replicon (data not shown). In the
CR5A replicon-transfected cells following drug selection, the mutant
CP-GFP fusion was detectably expressed in a high percentage of the
cells in the culture (88%) and exhibited a cytoplasmic distribution
with a tendency to form cytoplasmic foci in contrast to the native CP
(Fig. 1C, particularly in boxed region). Following selection CR5A
replicon-transfected cells exhibited the same growth properties as
did the RUBrep/GFP/neo-transfected cells, ie slow growth and difﬁ-
culty achieving conﬂuence (Fig. 1D). Staining with antibodies for
activated caspase-3 revealed no differences in the percentage of
apoptotic cells among the three drug-selected cell lines (GFP, C-GFP,
and CR5A-GFP) as 6% of the cells in all three cell lines exhibited
activated caspase-3 (vs o1% in Vero cells).
Replicon stability following release from drug selection and
IFN-a treatment
To determine if the replicons were stable in the culture in the
absence of the antibiotic, transfected cultures that had beenmaintained in medium containing antibiotic were transferred to
antibiotic-free medium and subsequently subcultured. When
transfected cultures released from antibiotic selection were
screened for the presence of replicon RNA by Northern blotting,
RUBrep/GFP/neo RNA eventually became undetectable, but
required twelve passes (Fig. 3). In contrast, RUBrep/C-GFP/neo
RNA was clearly detectable after twelve passes, although some-
what diminished in intensity in comparison with the culture prior
to release from the antibiotic.
Vero cells lack the b-IFN gene, but maintain the Type I IFN
receptor and thus are responsive to exogenously applied IFN. We
found that pretreatment of Vero cells with 1000 IU of IFN-a reduces
RUBV replication by tenfold (data not shown). To test the suscept-
ibility of the replicon to IFN, RUBrep/C-GFP/neo-transfected cells
were treated with increasing dosages of IFNa.(50, 100, 500, and
1000 IU) for one week in drug free medium (RUBrep/GFP/neo cells
were not used in these experiments because of their poor growth
properties). The culture used for analysis had been maintained for
12 weeks and roughly 15% of the cells in the culture were positive
for GFP. As a further test for presence of the replicon, a recently
developed ﬂuorescent in situ hybridization (FISH) assay (Matthews
and Frey, 2011) was employed which showed that 15–18% of the
cells in the culture contained detectable replicon RNA, demonstrat-
ing a correlation between RNA synthesis and GFP expression. As
shown in Figs. 4A and B, IFN-a decreased the number of GFP and
replicon positive cells as well as total GFP production (measured by
Western blot) in a dose-dependent manner. RT-PCR was also used as
a more sensitive assay to detect replicon RNA, but as shown in
Fig. 4C, replicon RNA was still detectable, on day 6 post-treatment,
albeit at a reduced level.
As there is still residual replicon RNA after one week of IFN-a
treatment, we continued incubation of RUBrep/C-GFP/neo cells
with 1000 IU of IFN-a for an additional four weeks, at which time
the replicon was undetectable by RT-PCR (Fig. 5A). To determine
if the replicon had been eliminated, the cells which had been
treated with IFN-a for ﬁve weeks were subcultured and either
maintained or released from treatment. One week after subcul-
ture, the presence of replicon was monitored by RT-PCR and
microscopically by FISH and GFP ﬂuorescence. To our surprise, the
replicon was restored after release from IFN treatment (Fig. 5B
and C). Particularly, as shown in Fig. 5C, the number of cells
expressing GFP and positive for FISH was similar to control
RUBrep/C-GFP/neo cells that had been maintained in parallel
without IFN treatment. Taken together, these data indicate that
while IFN-a suppresses replicon replication, it fails to cure the
cells of the replicon.
Fig. 4. Effect of IFN-a treatment on replicon stability. RUBrep/C-GFP/neo-trans-
fected cells were subcultured in the absence of G418 and treated with 0, 50, 100,
500, or 1000 IU/ml of IFN-a on the second day after seeding. Control Vero and
RUBrep/C-GFP/neo cells were maintained in the absence or presence of G418 as
indicated. Six days post IFN treatment, cells were assayed for GFP ﬂuorescence and
by FISH for the presence of replicon RNA (Panel A). To quantify the percentage of
positive cells, at least 200 cells from three different ﬁelds of view were counted.
The bars are the means from three independent experiments and the error bars
represent the standard deviation from the mean. Lysates of similarly treated
parallel cultures were assayed for GFP by Western blot (Panel B). Total cell RNA
extracted from control Vero cells or RUBrep/C-GFP/neo cells maintained in the
presence of G418, the absence of G418, or the absence of G418 in the presence of
1000 IU/ml of IFN-a for six days and assayed by RT-PCR using primers speciﬁc for
GFP, or b-actin (internal control) (Panel C).
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The strategy of engineering replicons expressing drug resis-
tance markers for selection of cultures uniformly harboring the
replicon has been used with a number of viruses and here we
applied it to RUBV. Selection of drug-resistant cells following
replicon transfection was readily achieved, as we had anticipated
considering the relatively noncytopathic nature of RUBV. These
cell lines have already been used in several studies on RUBV
replication (Claus et al., 2007; Fontana et al., 2010; Fontana et al.,
2007; Matthews et al., 2010). The RUBV replicons used in this
study were capable of expressing a protein in addition to the drug
resistance factor and we used this capability to study the RUBV
CP, a multifunctional protein with capacities exceeding formation
of the virion core (Ilkow et al., 2010b). We found that CP was
necessary for maximal cell survival during drug selection and for
growth equivalent to normal Vero cells following selection. Incontrast, replicons of the ﬂaviviruses Kunjin and West Nile virus
in which the virion structural proteins were replaced with a drug
resistance gene, drug selected cultures grew normally without
apparent cytopathic effect (Khromykh and Westaway, 1997; Shi
et al., 2002). In the case of the alphaviruses, corresponding
replicons of New World viruses such as western and Venezuelan
equine encephalitis viruses (WEEV and VEEV) yielded drug
selected cultures that were readily established without cytopathic
effect (Garmashova et al., 2007). However, replicons of Old World
alphaviruses such as Sindbis virus (SINV) and Semliki Forest virus
(SFV) required the selection of noncytopathic variants, mutations
in which were used to construct replicons which efﬁciently
generated drug selected cultures (Frolov et al., 1999; Perri et al.,
2000). This dichotomy among alphavirus replicons was based on
cell transcriptional shutdown determinants residing in the CP of
VEEV and WEEV (which was not included in the replicon) vs in
nsP2 of SINV and SFV (in which the noncytopathic mutations
occurred).
Inclusion of CP in the replicon speciﬁcally increased trans-
fected cell survival during drug selection by almost tenfold and
the resulting culture had a growth rate similar to Vero cells while
cells transfected with the replicon lacking CP grew at a much
slower rate and failed to reach conﬂuency without heavy seeding.
Considering the well described effect of CP on virus RNA synthesis
(Tzeng and Frey, 2003, 2005; Tzeng et al., 2006), we initially
hypothesized that CP enhanced replicon RNA synthesis and
concomitantly neoR drug resistance marker production. However,
we found SG RNA to be in similar abundance in cells transfected
with both replicons, both before and after drug selection (repli-
cons expressing CP produced more genomic RNA) as was the neoR
protein. Furthermore, the entirety of CP, including the C-terminal
E2 signal sequence, was needed for maximal survival during drug
selection whereas only the N-terminal 88 aa is needed for CP-
mediated enhancement of replicon RNA synthesis. Recently, Ilkow
et al. (2011) showed that CP exhibited inhibition of Bax-mediated
induction of apoptosis and that ﬁve R residues in the C-terminal
region of CP preceding the E2 signal sequence were necessary for
this activity. Introduction of R to A substitutions of these ﬁve
residues yielded a replicon that exhibited drug survival and
resulting culture growth rate similar to the replicon without CP.
Based on the studies of (Ilkow et al. (2011), we conclude that the
enhanced survival mediated by CP is due to its anti-apoptotic
activity. The mechanism behind the effect of CP on the growth of
the selected culture is not as obvious as these cultures did not
exhibit the characteristics of apoptotic RUBV-infected cells,
namely the presence of ﬂoating cells in the culture medium
(Pugachev and Frey, 1998), and shared an equivalent, low per-
centage of apoptotic cells as detected by activated caspase-3
assay (albeit higher than the control Vero cells). Thus, CP may
have additional pro-growth effects on the cell that are mediated
through these R residues. Another possibility is that CP, through
these R residues, modulates the known cytopathogenicity deter-
minants which reside on the P150 protein (see below), perhaps
through its ability to bind to P150 (Tzeng et al., 2006). As
indicated by the lower percentage of cells detectably expressing
GFP in the C-GFP replicon-transfected cultures in contrast to the
GFP and CR5A-GFP replicon transfected cultures, there may also
be a CP-mediated modulation of replicon gene expression, includ-
ing putatively P150, the mechanism of which is unknown at
this time.
Drug-selected, replicon-transfected cell lines have also been
used to elucidate mutations in the replicon genome which impact
the interaction of the replicon with the host cell. As described
above, mutations in nsP2 of Old World alphaviruses were neces-
sary to alter the cytopathogenicity of the replicon to allow for cell
survival (Frolov et al., 1999; Perri et al., 2000). In the case of
Fig. 5. Replicon recovery after release from long-term treatment with IFN-a. (A) RUBrep/C-GFP/neo cells were incubated with weekly subculturing for one to ﬁve weeks in
the presence of 1000 IU of IFN-a. Control Vero cells were similarly maintained for ﬁve weeks in the absence of G418 and control RUBrep/C-GFP/neo cells were similarly
maintained for ﬁve weeks in the absence of G418. Total cell RNA was isolated and assayed by RT-PCR using probes speciﬁc for GFP, or b-actin (internal control) (B) and (C).
After ﬁve weeks of IFN-a treatment, the RUBrep/C-GFP/neo cells were subcultured and either maintained for a sixth week in the presence of IFN-a or released from IFN
treatment by maintenance in normal medium (RLS). Control Vero and RUBrep/C-GFP/neo cells were maintained for a sixth week in the absence and presence of G418,
respectively. Total cell RNA was extracted and assayed by RT-PCR using primers speciﬁc for GFP and b-actin (B) or cells were examined by ﬂuorescence microscopy for GFP
expression or FISH to detect the presence of replicon RNA (C0. Quantition was done as in Fig.4A (C)).
W.-P. Tzeng et al. / Virology 429 (2012) 29–3634hepatitis C virus, mutations in the NS3, NS4a, and NS5b were
frequently encountered which were necessary to optimize repli-
cation of the replicon [reviewed in (Woerz et al., 2009)]. Muta-
tions in the NS2A protein of Kunjin virus were found to affect the
virus-induced inhibition of IFN-beta promoter-driven transcrip-
tion (Liu et al., 2004) In this regard, the RUBV CP was needed for
optimal cell survival and growth and we did not search for
optimizing mutations in other regions of the replicon genome.
However, for example, determinants of RUBV cytopathogenicity
in cell culture have been mapped to the P150 gene, in particular,
an opaque and clear plaque phenotype between variants of the
same strain of RUBV (Pugachev et al., 1997). The replicons used in
this study were derived from the clear plaque variant and thus it
is possible that mutations have been selected during passage of
the replicon-selected cells that reduce cytopathogenicity and
identiﬁcation of such attenuating mutations could be used to
speciﬁcally localize determinants of this phenotype.
We also used the drug-selected, replicon-transfected cultures to
assess the stability of the replicon following drug withdrawal. This
was of interest considering the capacity of RUBV for long-term
persistent infection both in cell culture (Mifune et al., 1970;
Stanwick and Hallum, 1974) and in vivo, particularly in congenitally
infected infants (Lee and Bowden, 2000). In cell culture, RUBV is able
to readily persistent infections in all cell lines tested and analysis of
replicon stability was done to gain insight into the innate ability of
RUBV to persist at the cell level in the absence of infectious particles
to renew the infection in cells in the culture that become cured. The
replicons were stable, even in the RUBrep/GFP/neo-transfected cells
which required 12 weeks for curing. We hypothesize that curing in
this cell line occurs when a daughter cell fails to receive a replicon
following cell division and, considering the relative growth advan-
tage that a replicon-free cell would have over a cell harboring the
RUBrep/GFP/neo replicon, the cured cells would take over thisculture. In the case of the RUBrep/C-GFP/neo transfected culture in
which the replicon-containing and free cells grow at equal rates,
cured cells would not have this advantage. RUBV is able to persist in
IFN-competent as well as IFN-deﬁcient cell lines (such as Vero) and
we thus tested the effect of exogenously applied IFN-a on replicon
stability using the RUBrep/C-GFP/neo cell line. IFN-a has been
shown to rapidly inhibit HCV replicon RNA replication in HCV
replicon-stable cell lines and prolonged IFN-a treatment (4 pas-
sages) leads to curing the cultures of the replicon (Blight et al., 2002;
Frese et al., 2001; Kato et al., 2003). We found that IFN-a treatment
rapidly downregulated replicon-speciﬁc RNA and protein synthesis
and eventually eliminated evidence of the replicon, but ﬁve weeks
were required. Then, surprisingly, the replicon reappeared within
one week of suspension of IFN-a treatment. The detection limit of
our RT-PCR assay is 1 pg of ss genomic replicon RNA, corresponding
to 0.06 genomic copies per cell as 3X106 cells were used in the
curing experiments shown in Fig. 5A. We suggest that the replicon
persisted as dsRNA, which would be undetectable by RT-PCR as the
GC content of the RUBV genome is 70%. Both Mifune et al. and
Stanwick and Hallum (Mifune et al., 1970; Stanwick and Hallum,
1974) also found that treatment of RUBV-persistently infected Vero
cells with IFN reduced virus replication and eliminated evidence of
virus after 2–3 weeks as detected by infectious virus in the culture
medium and RUBV-antigen expressing cells. In the Stanwick and
Hallum study, however, cells remained cured of virus after release
from IFN treatment. It is possible that the RUBrep/C-GFP/neo-
transfected cultures would be cured by additional IFN-a treatment,
but this discrepancy with our ﬁnding may also be related to the type
of IFN used. Both of these previous studies obtained IFN by induction
of BSC1 cells, another African green monkey kidney cell line, by poly
IC treatment while we used a recombinant IFN-a. Interestingly,
Stanwick and Hallum found that other cells persistently infected
with RUBV [BSC1, BHK (hamster)(these cells lack the type I IFN
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similar levels of exogenously applied IFN. In toto, RUBV persistent
infection in cell culture is surprisingly refractory to IFN treatment,
likely contributing to the ability of RUBV to establish a persistent
infection.Materials and methods
Cells, replicons, and drug selection
Vero cells were maintained in Dulbecco minimal essential
medium (Invitrogen, Rockville, Md.) supplemented with 5% fetal
bovine serum (FBS) and gentamicin (10 mg/ml; Invitrogen) while
BHK cells were maintained in Dulbecco minimal essential med-
ium supplemented with 10% FBS and gentamicin (10 mg/ml). The
replicons used in the study, RUBrep/GFP/neo and RUBrep/C-GFP/
neo, have been previously described (Fontana et al., 2007) while
RUBrep/C(-S)GFP/neo was constructed by substituting the corre-
sponding fusion protein gene from RUBrep/C(1–277)GFP (Tzeng
and Frey, 2003) into RUBrep/C-GFP/neo. The CR5A mutation,
which substituted A’s for R’s as residues 264, 268, 271, 275, and
277 of CP (Ilkow et al., 2011) was introduced into RUBrep/C-GFP/
neo using previously described strategies (Tzeng and Frey, 2003).
RUBrep/GFP/pac and RUBrep/C-GFP/pac were generated by repla-
cing the neoR gene with the puromycin acetylase gene [obtained
from I. Frolov;(Chen et al., 2004)]. Following transfection with
in vitro replicon transcripts as previously described (Tzeng and
Frey, 2002), drug selection was done using medium containing
1200 mg/ml of G418 or 2 mg/ml of puromycin. Following selection,
the replicon transfected cells were maintained in medium con-
taining the drugs at these respective concentrations. Cloned cells
lines were derived from colonies with maximal GFP expression,
however experiments were done on the uncloned population
except where indicated. Cell cycle analysis was done using
propidium iodine staining. Brieﬂy, cells (5105/ml) were har-
vested, ﬁxed with ethanol for 10–15 min at 20 1C and RNA was
removed by addition of RNase A (10 mg/ml, Sigma). Cells were
pelleted and resuspended in propidium iodide solution (2.5 mg/
ml, Sigma). The analysis was performed by using a FACScanto
ﬂow cytometer (Becton Dickinson) and the FACSDiva research
software (Hofmann et al., 1999; Suzuki et al., 1997).
To test the relative efﬁciency of cell survival following trans-
fection and drug selection, a ‘‘reverse plaque assay’’ was utilized
(Chen et al., 2004). Brieﬂy, 90% conﬂuent monolayers were
transfected with equal amounts of in vitro replicon transcripts.
Four days post-transfection, the cells were trypsinized, adjusted
to equivalent cell concentrations, and a series of threefold dilution
were made in medium. Equal aliquots of each dilution were
plated in drug-containing medium and the cell density generated
from each dilution was visualized by crystal violet staining 1–2
weeks post plating.
IFN-a treatment
To test the effect of IFN on replicon stability, RUBrep/C-GFP/
neo cells were incubated in medium containing ‘‘Universal Type I
IFN’’, an IFN-a hybrid constructed from recombinant Human IFN-
aA and Human IFN-a D (PBL Interferon Source).
Detection of virus-speciﬁc macromolecules
Northern blot of analysis of isolated total cell RNA and
Western blot analysis of cell lysates were done as previously
described (Tzeng et al., 2001) and (Tzeng et al., 2006), respec-
tively. Rabbit anti-neomycin phosphotransferase (neoR factor)were obtained from Upstate Biotechnology and used at a 1:500
dilution, rabbit anti-GFP antibodies were obtained from Clonetech
and used at a 1:50 dilution while rabbit anti-GADPH antibodies
were obtained from Abcam and used at a 1:5000 dilution. The
FISH assay which is used to detect replicon RNA in individual cells
was done as described in (Matthews and Frey, 2011). Fluores-
cently labeled cells (GFP or FISH) were visualized using a Zeiss
Axioplan microscope with epiﬂuorescence capacity. RT-PCR was
done using protocols described in (Pugachev et al., 1997). Speci-
ﬁcally, ﬁrst strand cDNA synthesis was primed using downstream
primers 50-CTGAAGATCTTCATTACTTGTACAGCT-30 (GFP) ampliﬁ-
cation proceeding using the downstream primers and upstream
primer 50-ATATACTAGTATGGTGAGCAAGGGCG-30 (GFP).Acknowledgments
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